Results 91 to 100 of about 4,832 (178)

Benralizumab Depletes IL‐5Rα‐Bearing Cells in Skin Lesions of Patients With Atopic Dermatitis

Clinical and Translational Allergy
Background Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by tissue eosinophilia and itch. We evaluated the effect of eosinophil depletion with benralizumab on markers of inflammation in the skin of patients with AD.
Christiane E. Whetstone, Ruth P. Cusack, Emma L. Price, Karen J. Howie, Caitlin Stevens, Dhuha Al‐Sajee, Suzanne Beaudin, Jennifer Wattie, Nadia Alsaji, Abbey Schlatman, Vanessa Luk, Paul M. O'Byrne, Mark D. Inman, Roma Sehmi, Hermenio Lima, Gail M. Gauvreau   +15 more
doaj   +1 more source

Case Report: Benralizumab combined with a steroid-sparing strategy in a case of severe eosinophilic granulomatosis with polyangiitis

Frontiers in Immunology
BackgroundEosinophilic granulomatosis with polyangiitis (EGPA) is a rare anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis characterized by eosinophilic inflammation and necrotizing vasculitis.
Nanxi Zhou, Chunxiao Fang, Min Feng, Chang Dong   +3 more
doaj   +1 more source

A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma

, 2015
BACKGROUND: Patients with frequent asthma exacerbations resulting in emergency department (ED) visits are at increased risk for future exacerbations. We examined the ability of 1 dose of benralizumab, an investigational antiinterleukin 5 receptor alpha ...
Kim, K., Fiening, J. P., Parker, J. M., Molfino, N. A., Smithline, H., Silverman, R. A., Nowak, R. M., Khan, F., Rowe, B. H.   +8 more
core   +1 more source

Real-world comparative effectiveness of biologic therapies in severe asthma: EU-ADVANTAGE

ERJ Open Research
Background In Europe, although multiple biologics have been approved for the treatment of severe asthma (SA), comparative data from real-world settings remain limited. This study compared the real-world effectiveness of dupilumab with that of omalizumab,
Giorgio Walter Canonica, Johann Christian Virchow, Arnaud Bourdin, Juby Jacob-Nara, Kinga Borsos, Richard H. Stanford, Zhixiao Wang, Mena Soliman, Lynn Huynh, Fariha Haque, Mei Sheng Duh, Wei-Han Cheng   +11 more
doaj   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Eosinophilic granulomatosis with polyangiitis developed during treatment with benralizmab for severe asthma: A case report and literature review

Respirology Case Reports
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare autoimmune disorder characterized by necrotizing vasculitis, asthma, and eosinophilia. We report a case of EGPA that developed during benralizumab treatment for severe asthma and provide a ...
Mitsukuni Sakabe, Kazunori Tobino, Yumi Obata, Shota Sogabe, Kazuki Uchida, Yosuke Murakami   +5 more
doaj   +1 more source

Effect of Benralizumab on Mucus Plugs in Severe Eosinophilic Asthma

Introduction: Mucus plugs are associated with airway obstruction in severe asthma and are involved in the formation of activated eosinophils. Benralizumab, an anti-interleukin-5 receptor antibody, markedly reduces not only peripheral blood eosinophils ...
酒井, 菜摘, Sakai, Natsumi
core  

Biologic Switching in Patients with Severe Asthma: Effects on Exacerbations, Corticosteroid Use and Lung Function. [PDF]

J Clin Med
Dindar Çelik F, Aksu K.
europepmc   +1 more source

One size does not fit all: uncontrolled T2 inflammation on tezepelumab-a case series. [PDF]

Allergy Asthma Clin Immunol
Tardif A, Boulay ME, Côté A, Godbout K.   +3 more
europepmc   +1 more source

A case of herpes zoster following the first dose of benralizumab. [PDF]

Allergol Select
Aksu K, Telli O, Yağdıran M, Dindar Çelik F, Çelik Tuğlu H, Göktürk Ö.   +5 more
europepmc   +1 more source